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Several  laboratories  have  now  demonstrated  antibody-dependent  enhance- 
ment (ADE) l of flavivirus replication in cells of the monocyte-macrophage (M4~) 
lineage  and  in  M4~-like  cell  lines  (1-4).  Antivirat  IgG,  but  not  IgM,  has  been 
implicated; the phenomenon depends on the Fc portion of the IgG molecule (1, 
5), and is blocked by a  monoclonal antibody directed against the trypsin resistant 
mouse Fc receptor (6). 
To investigate the possibility that, under physiological conditions, complement 
receptors  might  mediate  ADE,  we  have examined  replication  of the  flavivirus 
West Nile virus (WNV) in  macrophages that are known to possess both  Fc and 
complement  receptors  (7-10).  We  show  here  that  antiviral  IgM  can  mediate 
ADE in  the  macrophagelike cell  line  P388D1,  in  the  presence of fresh normal 
serum, and we present evidence that at least one complement receptor,  CR3 is 
involved. 
Materials and  Methods 
Cells.  P388D1 cells were grown in Dulbecco's modification of Eagle's minimal essential 
medium (DME) supplemented with 2 mM glutamine,  10% heat-inactivated (56°C for 30 
min) fetal bovine serum (HIFBS) with  100 U/ml penicillin,  100/,g/ml streptomycin and 
100 #g/ml kanamycin. L929 cells were grown in Eagle's minimal essential medium with 
3% HIFBS, and antibiotics as above. 
Virus.  West Nile virus (WNV; Egypt  101  strain) was used as a  9,000 g supernate of 
infected suckling mouse brain homogenate, frozen in aliquots at -70°C. 
Antibodies.  Rabbit anti-WNV IgM was prepared from the serum of a  New Zealand 
White rabbit collected 6 d  after the intravenous inoculation of 8  x  106 plaque-forming 
units  (pfu) of live  WNV.  The  serum  was passed  through  a  Sephacryl  $300  superfine 
column at a  flow rate of 13 ml/h.  The forward shoulder of the first protein peak was 
collected and concentrated  10-fold on a  PM10  filter in an Amicon ultra-filtration cell. 
Purity  of  the  IgM  was  confirmed  on  an  sodium  dodecyl  sulfate-polyacrylamide gel 
electrophoresis  (SDS-PAGE)  gel  and  by  immunoelectrophoresis  using  goat  anti-rabbit 
whole serum (Miles  Laboratories, Slough, U.K.). This preparation of IgM had a neutral- 
ization  titer  (PRNTs0)  of  1:160  as  determined  in  L929  mouse  fibroblast cells,  and  a 
haemagglutination inhibition titer of 1:80. 
F7/3  is a  mouse  IgG1  monoclonal  antibody characterized  by Peiris et al.  (I 1)  and 
purified on a protein-A-Sepharose CL 4B column by the method of Ey et al. (12). 
Abbreviation,s used m this p,tper: ADE, antibody-dependent  enhancement; CR3, monocyte-macro- 
phage complement receptors;  CVF, cobra venom factor; DME, Dulbecco's modification of Eagle's 
n~inimal essential medium; HIFBS, heat-inactivated fetal bovine serum; M4~, mon.ocyte macrophage; 
PBS, phosphate-buffered  saline; pfu,  plaque-forming  units; SDS-PAGE, sodium  dodecyl sulfate- 
polyacrylamide gel electrophoresis; WNV, West Nile virus. 
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The hybridoma cell lines M 1/70 (13) and 2.4G2 (14) were generously provided by Dr. 
T. A. Springer,  Boston and Dr. J. C. Unkeless, New York, respectively. 
Complement.  Fresh normal serum from DBA/2 C5-deficient mice was used as a source 
of complement. 
Cobra Venom Factor.  A purified preparation was generously  provided  by Professor 
Otto G6tze, G6ttingen, FRG. 
Enhancement Assay.  WNV at 200-300 pfu/ml (as measured by conventional assay on 
a pig kidney cell line [PS]; reference 15) was mixed with an equal volume of rabbit anti- 
WNV IgM at  1:40 dilution, or diluent,  and incubated  at 37°C for 45 min. Aliquots of 
these mixtures, 0.1  ml, were applied to two to four preformed cell monolayers followed 
immediately by 0.1  ml of a  1:3 dilution of fresh or heat-inactivated (56°C for 30 min) 
DBA/2 mouse serum.  After 2 h at 37°C  monolayers were washed twice with PBS to 
remove residual virus, a carboxymethylcellulose overlay medium was added, and prepa- 
rations  were  incubated  at  37°C  for  3  d,  at  which  time  plaques  were  stained  with 
naphthalene black and counted. 
Results 
When IgM at a  dilution of 1:40  was incubated with WNV and the residual 
infectivity of the mixture assayed on L929 fibroblasts, neutralization occurred, 
which was further potentiated in the presence of fresh normal serum obtained 
from DBA/2 C5-deficient mice, as would be expected (Fig. 1 a) (16).  When the 
Mq5 line P388D1  was infected under the same conditions, however, there was a 
5-10-fold increase in plaques produced by mixtures containing IgM, virus, and 
fresh serum (Fig. 1 b). Serum heat inactivated at 56°C for 30 min did not mediate 
this increase. Control infections in which virus was incubated without IgM and 
presented  to  the  cells  in  the  presence  of fresh  normal  serum  did  not  show 
increased  viral  replication.  Fresh  serum  diluted  1:2  to  1:12  was  capable  of 
enhancing viral replication; IgM enhanced viral replication when used at 1:10 to 
1:160, neutralization was never observed with P388D1  cells  in the presence of 
fresh normal serum (data not shown). 
To further investigate the nature of the heat labile component(s) responsible 
for  this  effect, we  utilized  highly purified cobra  venom  factor  (CVF)  which 
consumes mainly C3 in the C5-deficient mouse serum used here. Fresh serum 
treated with CVF did not enhance replication of the IgM-virus mixtures (Fig. 
1 c). 
Once activated by limited proteolysis, complement components, C3, C4, and 
the anti-proteinase  a2  macroglobulin bind covalently to  other  molecules in  a 
reaction mediated by an activated thiol ester.  Nucleophiles that react with this 
thiol ester prevent covalent binding to other molecules (17).  We used the strong 
nucleophile sodium salicylhydroxamate to compete with virus mixtures for the 
covalent binding site of the serum  components involved. The ADE  observed 
with  IgM-virus-fresh  serum  was  decreased  with  increasing  concentrations of 
sodium salicylhydroxamate and was completely abolished by 0.7 mM of the salt, 
which did not affect macrophage viability or viral growth in the absence of fresh 
serum (data not shown). Abrogation of ADE by CVF and by sodium salicylhy- 
droxamate are compatible with a role for C3. 
Investigations of the M~b membrane receptors that might be implicated indicate 
that CR3, which recognizes iC3b (a rapidly formed major fragment of activated 
C3) is involved in the binding step. When P388D1  cells were preincubated with 260  CARDOSA  ET  AL.  BRIEF  DEFINITIVE  REPORT 
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FIGURE  1.  Virus yields obtained when cell monolayers were infected with IgM +  virus, or 
virus only,  in  the presence  of fresh  (open  columns) or  heat  inactivated (hatched  columns) 
mouse serum; in  la  L929  cells were used,  and  in  lb  P388D1  cells,  c shows plaque counts 
obtained when virus +  IgM (dotted columns), or virus + diluent (hatched columns) were used 
in combination with (a) fresh  DBA/2 serum incubated for  15  rain at 37°C with CVF (final 
concentration  9.1  g/ml); (b)  fresh  DBA/2 serum  mock-treated with diluent;  (c)  untreated 
DBA/2 serum; or (d) heat-inactivated DBA/2 serum.  In every case the final serum concen- 
tration was  1:3.  Bars indicate range of three to four assays. 
M1/70,  which  inhibits  CR3-mediated  binding  of  opsonized  erythrocytes  (13) 
ADE  of  the  IgM-virus-fresh  serum  mixture  was  abolished,  whereas  2.4G2, 
directed  against  the  trypsin-resistant  Fc  receptor  04)  had  no  effect  (Fig.  2a). CARDOSA  ET  AL.  BRIEF  DEFINITIVE  REPORT  261 
I~  IgM4-vlrus 
virus only 
I~  IgM+virus 
virus only 
I).f.u/ml (xlO0) 
'  I  ' 
p.f.u./ml (xlO0) 






i  1"1"  virus !  ~r  ~  g  ~  ~~ 
virus, only 
t~  +virus  ~a  IgG1 
virus only  ,~, 
FmVRE  2.  Receptor blocking studies. Preformed P388D1  monolayers held on an ice tray 
were  treated  for  60  min with  DME  containing 20%  supernatant fluids from  hybridomas 
producing antibodies (a) M1/70 (anti Mad) or (b) 2.4G2 (anti-trypsin-resistant Fc receptor), 
then washed with ice-cold DME and infected with West Nile virus with or without anti-WNV 
antibodies, in the presence of fresh [] or heat-inactivated [] DBA/2 serum. In a, the antibody 
was anti-WNV IgM. In b, the antibody was a monoclonal anti-WNV IgG~. Bars indicate range 
of duplicate assays. 
Under our experimental conditions, neither M 1/70 nor 2.4G2 affected controls 
in the absence of IgM. In contrast, ADE mediated by IgG1 was not affected by 
either fresh serum or M1/70  but was abrogated by 2.4G2 antibody. Since the 
cells were preincubated with the monoclonal antibodies M 1/70 and 2.4G2 and 
washed free of unbound  antibody before introduction of virus,  these studies 
implicate macrophage CR3 in IgM-serum enhanced replication of WNV. 
Discussion 
In these studies the magnitude of the enhancement system is much less than 
in  IgG-mediated ADE.  However, 20-50-fold enhancement has been observed 
when thiog]ycollate-elicited, but not resident, mouse peritoneal macrophages are 262  CARDOSA ET  AL.  BRIEF  DEFINITIVE REPORT 
infected with virus-IgM-fresh serum (unpublished observations). These differ- 
ences may be related to observations that certain Mq~ ingest opsonized particles 
readily via Fc receptors (7,  9) but fail to ingest particles bound via complement 
receptors (7,  9,  10) unless the cells are stimulated by various treatments (9,  18- 
20) or the particles coated with both IgG and complement (10). 
In the experiments presented here, we have deliberately separated Fc receptor- 
dependent ADE, mediated by IgG, from enhancement via complement receptors 
and IgM. The two enhancement pathways are not mutually exclusive, but may 
act  synergistically when  certain  classes  of IgG  fix  complement.  Complement 
receptors are found on many cell types (21)  (erythrocytes, lymphocytes, neutro- 
phils, monocytes, macrophages, kidney epithelial cells) and there may be several 
different complement receptors  on  each  cell  type.  Although it  remains to be 
shown that other complement receptors can also mediate enhanced viral repli- 
cation, we suspect that enhancement via complement receptors may be a general 
phenomenon. Since some enveloped viruses are able to activate complement in 
the absence of antibody (22,  23),  such a  route of virus penetration should be 
considered seriously in other systems. 
Summary 
Evidence is  presented  that  M4~  complement receptors  (CR3)  mediate  IgM- 
dependent enhancement of flavivirus replication in the presence of complement. 
Enhancement  is  blocked  by  pretreatment  of macrophages  with  monoclonal 
antibody M1/70,  which  inhibits CR3  binding,  but  not  by pretreatment  with 
monoclonal antibody 2.4G2, which inhibits FcR binding. 
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